---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019020"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:06:10.697291+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially

## Summary
- EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.
- GAAP net loss $18.1M ($0.40/share); non-GAAP adjusted loss $9.4M ($0.21/share).
- Cash $24.8M at quarter end; subsequent $11.6M from Series B-1 offering.
- MolDX pre-submission meeting scheduled July 17, 2024 for EsoGuard coverage.
- EsoGuard test volume 2,420, +10% sequentially and +31% YoY.

## SEC filing metadata
- accession: 0001493152-24-019020
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/0001493152-24-019020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019020
- JSON: https://secwatch.observer/filing/0001493152-24-019020.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019020.txt

## Key facts
- Earnings Releases
  Lucid Diagnostics Inc. reported the three months ended March 31, 2024 results: revenue $1.0 million, net income $18.1 million or $(0.40) per common share, EPS $(0.40) per common share.
  - Period: the three months ended March 31, 2024
  - Revenue: $1.0 million
  - Net income: $18.1 million or $(0.40) per common share
  - EPS: $(0.40) per common share
  - Result: reported results
  source text: regional plans in biomarker legislation states and pilots with national plans. Financial Results ● For the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $11.8 million, which included stock-based compensation expenses of $0.9 million. GAAP net loss attributable to common stockholders was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/0001493152-24-019020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.